Factor X and its deficiency states

Haemophilia

Volumn 3, Issue 3, 1997, Pages 159-172

  Perry, D J ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Deficiency; Diagnosis; Factor X; Gene; Treatment

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; PROTHROMBIN; SERINE PROTEINASE; VITAMIN K GROUP;

AMYLOIDOSIS; AUTOSOMAL RECESSIVE INHERITANCE; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 10 DEFICIENCY; CHROMOSOME 13Q; DISEASE ASSOCIATION; GENE STRUCTURE; HUMAN; PRIORITY JOURNAL; REVIEW; SEQUENCE HOMOLOGY; THROMBOSIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 0030869473     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1997.00106.x     Document Type: Review

References (114)

1. Telfer TP, Denson KW, Wright DR. A new 'coagulation' defect. Br J Haematol 1956; 2: 308-16.
2. Hougie C, Barrow HM, Graham JB. Stuart Clotting defect. Segregation of a hereditary hemorrhagic state from the heterozygous heretofore called 'stable factor' (SPCA, proconvertin factor VII deficiency). J Clin Invest 1957; 36: 485-93.
3. Duckert F, Fluckiger P, Koller F. Le role de facteur X dans la formation de la thromboplastine sanguine. Revue d'Hématologie 1954; 9: 489-92.
4. Wright IS. The nomenclature of blood clotting factors. Thromb et Diath Haemorr 1962; 7: 381-2.
5. Pfeifer RA, Ott R, Gilgenkrantz S, Alexandre P. Deficiency of coagulation factor-VII and factor-X associated with deletion of a chromosome 13 (q34) - evidence from 2 cases with 46,xy,t(13-y) (q11-q34). Hum Genet 1982; 62: 358-60.
6. Ott R, Pfeifer RA. Evidence that activities of coagulation factors VII and X are linked to chromosome 13 (q34). Hum Hered 1984; 34: 123-6.
7. Scambler PJ, Williamson R. The structural gene for human coagulation factor X is located on chromosome 13q34. Cytogenet Cell Genet 1985; 39: 231-3.
8. de Grouchy J, Dautzenberg MD, Turleau C, Beguin S, Chavin CF. Regional mapping of clotting factors VII and X to 13q34. Expression of factor VII through chromosome 8. Human Genet 1984; 66: 230-3.
9. Miao CH, Leytus SP, Chung DW, Davie EW. Liver-specific expression of the gene coding for human factor X, a blood coagulation factor. J Biol Chem 1992; 267: 7395-401.
10. Fung MR, Hay CW, MacGillivray RT. Characterization of an almost full-length cDNA coding for human blood coagulation factor X. Proc Natl Acad Sci USA 1985; 82: 3591-5.
11. Leytus SP, Chung DW, Kisiel W, Kurachi K, Davie EW. Characterization of a cDNA coding for human factor X. Proc Natl Acad Sci USA 1984; 81: 3699-702.
12. Bahnak BR, Howk R, Millstein L, Edgington TS, Jaye MC, Drohan WW, Fair DS. Characterization of a human factor-X cDNA clone and analysis of factor-X transcription by human hepatoma-cells. Thromb Haemost 1985; 54: 168.
13. Messier TL, Pittman DD, Long GL, Kaufman RJ, Church WR. Cloning and expression in COS-1 cells of a full-length cDNA encoding human coagulation factor X. Gene 1991; 99: 291-4.
14. Jagadeeswaran P, Rao KJ, Zhou ZQ. Characterization of factor-X deficiency mutation by use of inexpensive PCR device. Thromb Haemost 1989; 62: 294.
15. Patthy L. Evolution of the proteases of blood coagulation and fibrinolysis by assembly from modules. Cell 1985; 41: 657-63.
16. Furie BM, Furie BC. The molecular basis of blood coagulation. Cell 1988; 53: 505-18.
17. Breathnach R, Chambon P. Organization and expression of eukaryotic split genes coding for proteins. Ann Rev Biochem 1981; 50: 349-83.
18. Huang MN, Hung HL, Stanfield-Oakley SA, High KA. Characterization of the human blood coagulation factor X promoter. J Biol Chem 1992; 267: 15440-6.
19. Kaul RK, Hildebrand B, Roberts S, Jagadeeswaran P. Isolation and characterization of human blood-coagulation factor X cDNA. Gene 1986; 41: 311-4.
20. Leytus SP, Foster DC, Kurachi K, Davie EW. Gene for human factor X: a blood coagulation factor whose gene organization is essentially identical with that of factor IX and protein C. Biochemistry 1986; 25: 5098-102.
21. Tuddenham EGD, Copper DN. The Molecular Genetics of Haemostasis and its Inherited Disorders. Oxford: Oxford University Press, 1994.
22. Hay CW, Robertson KA, Fung MR, MacGillvray RTA. RFLPs or PstI and EcoRI in the human blood clotting factor X gene. Nucl Acids Res 1986; 14: 5118.
23. Hassan HJ, Guerriero R, Chelucci C, et al. Multiple polymorphic sites in factor IX locus. Blood 1988; 71: 1353-6.
24. Jaye M, Ricca G, Kaplan R, et al. Polymorphism associated with the human coagulation factor-X (f10) gene. Nucl Acids Res 1985; 13: 8286.
25. Wallmark A, Rose VL, Ho C, High KA. A NIaIV polymorphism within the human Factor X gene. Nucl Acids Res 1991; 19: 4022.
26. Fair DS, Banak BR. Human hepatoma-cells secrete single chain factor-X, prothrombin, and antithrombin-III. Blood 1984; 64: 194-204.
27. Graves CB, Munns TW, Willingham AK, Strauss AW. Rat factor-X is synthesized as a single chain precursor inducible by prothrombin fragments. J Biol Chem 1982; 257: 3108-13.
28. Sinha U, Wolf DL. Carbohydrate residues modulate the activation of coagulation factor-X. J Biol Chem 1993; 268: 3048-51.
29. Stenflo J, Suttie JW. Vitamin K-dependent formation of gamma-carboxyglutamic acid. Ann Rev Biochem 1977; 46: 157-72.
30. Fernlund P, Stenflo J. β-hydroxyaspartic acid in vitamin K dependent proteins. J Biol Chem 1983; 258: 12509-12.
31. McMullen BA, Fujikawa K, Kisiel W, et al. Complete amino-acid-sequence of the light chain of human-blood coagulation factor-X - evidence for identification of residue-63 as beta-hydroxyaspartic acid. Biochemistry 1983; 22: 2875-84.
32. Di Scipio RG, Hermodson MA, Yates SC, Davie EW. A comparison of human prothrombin factor IX (Christmas factor), factor X (Stuart factor) and protein S. Biochemistry 1977; 16: 698-706.
33. Padmanabhan K, Padmanabhan KP, Tulinsky A, et al. Structure of human des(1-5) factor Xa at 2.2Å resolution. J Mol Biol 1993; 232: 947-66.
34. James HL. Factor-X Friuli - possible structure-function correlates using the X-ray crystal-structure of normal factor-X. Thromb Haemost 1993; 69: 617.
35. Fujikawa K, Coan MH, Legaz ME, Davie EW. The mechanism of activation of bovine factor X (Stuart factor) by intrinsic and extrinsic pathways. Biochemistry 1974; 13: 5290-9.
36. Kisiel W, Hermondson MA, Davie EW. Factor X activating enzyme from Russell's viper venom: isolation and characterization. Biochemistry 1976; 15
37. Philippou H, Adami A, Boisclair MD, Lane DA. An ELISA for factor X activation peptide: application to the investigation of thrombogenesis in cardiopulmonary bypass. Br J Haematol 1995; 90: 432-7.
38. Fujikawa K, Titani K, David EW. Activation of bovine factor X (Stuart factor): conversion of activation of factor Xaα to Xaβ. Proc Natl Acad Sci USA 1975; 72: 3359-63.
39. Rao LV, Rapaport SI. Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci USA 1988; 85: 6687-91.
40. Broze GJ. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor X complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988; 71: 335-43.
41. Komiyama Y, Pedersen AH, Kisiel W. Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids and tissue factor. Biochemistry 1990; 29: 9418-25.
42. m on tissue factor. J Biol Chem 1980; 255: 5703-7.
43. 2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. J Biochem 1990; 265: 327-36.
44. Radcliffe RD, Nemerson Y. Activation and control of factor VII by activated factor X and thrombin. Isolation and characterization of a single chain form of factor VII. J Biol Chem 1975; 250: 388-95.
45. van Diejen G, Tans G, Rosing J, Hemker HC. The role of phospholipid and FVIIIa in the activation of bovine factor X. J Biol Chem 1981; 256: 3433-42.
46. Ahmad SS, Rawala-Sheilkh R, Walsh PN. Comparative interactions of factor IX and factor IXa with human platelets. J Biol Chem 1989; 13: 5290-9.
47. Ahmad SS, Rawala-Sheikh R, Walsh PN. Components and assembly of the factor X activating complex. Semin Thromb Haemost 1992; 18: 311-23.
48. Jackson CM. Factor-X. Prog Haemost Thromb 1984; 7: 55-109.
49. Fujikawa K, Legaz ME, Davie EW. Bovine factor X (Stuart factor): mechanism of activation of a protein from Russell's viper venom. Biochemistry 1974; 11: 4892-9.
50. Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry 1985; 24: 5558-67.
51. Brodsky GL, Bajaj SP. Determination of number of gamma-carboxyglutamic acid (gla) residues involved in forming the 2 high-affinity metal-binding sites in prothrombin and factor-X. Thromb Haemost 1987; 58: 312.
52. Jesty J, Lorenz A, Rodriguez J, Wun T-X. Initiation of the tissue factor pathway of coagulation in the presence of heparin: control by antithrombin III and tissue factor pathway inhibitor. Blood 1996; 87: 2301-7.
53. Rapaport SI. The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation. Thromb Haemost 1991; 66: 6-15.
54. Sprecher CA, Kisiel W, Matthews S, Foster DC. Molecular cloning expression and partial characterisation of a second human tissue-factor pathway inhibitor. Proc Natl Acad Sci USA 1994; 91: 3353-7.
55. Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII: correlation of specific cleavages by thrombin, factor Xa and activated protein C with activation and inactivation of factor VIII:C activity. Biochemistry 1686; 25: 505-12.
56. Girolami A, Bareggi G, Borsato M. Factor X Friuli: an immunological study in plasma and in serum using several methods. Blut 1975; 30: 203-12.
57. Denson KWE. The levels of factor II, VII, IX and X by antibody neutralization techniques in the plasma of patients receiving phenidione therapy. Br J Haematol 1971; 20: 643-8.
58. Fair DS, Plow EF, Edgington TS. Combined functional and immunochemical analysis of normal and abnormal human factor X. J Clin Invest 1979; 64: 884-94.
59. Girolami A, Ruzza G, Cappellato MG, Vicarioto MA. Factor X antigen evaluation by means of a laser nephelometer in health and disease. Clin Chim Acta 1985; 148: 125-30.
60. Girolami A, Vicarioto MA, Ruzza G, Vergolani A, Boeri G. Excess of factor X antigen versus clotting counterpart in coumarin treated patients as determined by an ELISA method. Folia Haematol 1985; 112: 326-32.
61. Girolami A, Cappellato MG, Lazzaro AR, Simioni P. Factor X antigen - factor X activity discrepancy in coumarin treated patients. No relationship with dilution curve. Folia Haematol 1987; 114: 126-33.
62. Aurell L, Simonsson R, Arielly S, Karlsson G, Friberger P, Cleason G. New chromogenic substrates for factor Xa. Haemostasis 1978; 7: 92-4.
63. Friberger P, Lenne L. A chromogenic factor X assay with new standardised reagents. Thromb Haemostas 1979; 42: 54.
64. Girolami A, Saggin L, Boeri G. Factor X assays using chromogenic substrate S-2222. Am J Clin Pathol 1980; 73: 400-2.
65. Fair DS, Edgington TS. Heterogeneity of hereditary and acquired factor X deficiencies by combined immunochemical and functional analyses. Br J Haematol 1985; 59: 235-48.
66. Graham JB, Barrow EM, Hougie C. Genetic aspects of a 'new' hemorrhagic state. J Clin Invest 1957; 36: 497-503.
67. Bernardi F, Marchetti G, Patracchini P, et al. Partial gene deletion in a family with factor X deficiency. Blood 1989; 73: 2123-7.
68. Wieland K, Millar DS, Grundy CB, Mibashan RS, Kakkar VV, Cooper DN. Molecular genetic analysis of factor X deficiency: gene deletion and germline mosaicism. Hum Genet 1991; 86: 273-8.
69. San Antonio. Blood 1989; 74: 1486-90.
70. Fair D, Revak D, Edgington T, Girolami A. Structural studies on the factor-X Friuli variant. Thromb Haemost 1983; 50: 272.
71. Girolami A, Lazzarin M, Procidano M, Luzzatto G. A family with heterozygous factor-X Friuli defect outside Friuli. Blut 1983; 46: 149-54.
72. Fair DS, Revak DJ, Hubbard JG, Girolami A. Isolation and characterization of the factor X Friuli variant. Blood 1989; 73: 2108-16.
73. James HL, Girolami A, Fair DS. Molecular defect in coagulation factor X (Friuli) results from a substitution of serine for proline at position 343. Blood 1991; 77: 317-23.
74. Santo Domingo. Evidence that the severe clinical phenotype arises from a mutation blocking secretion. J Clin Invest 1991; 88: 1685-9.
75. Racchi M, Watzke HH, High KA, Lively MO. Human coagulation factor X deficiency caused by a mutant signal peptide that blocks cleavage by signal peptidase but not targeting and translocation to the endoplasmic reticulum. J Biol Chem 1993; 268: 5735-40
76. Daly M, Bruce D, Perry DJ, et al. Antithrombin Dublin (-3 Val-Glu): an N-terminal variant which has an aberrant signal peptidase cleavage site. FEBS Lett 1990; 273: 87-90.
77. Watzke HH, Lechner K, Roberts HR, et al. Molecular defect (Gla+14-Lys) and its functional consequences in a hereditary factor X deficiency (factor X "Vorarlberg"). J biol Chem 1990; 265: 11982-9.
78. Marchetti G, Castaman G, Pinotti M, et al. Molecular basis of CRM+ factor X deficiency: a frequent mutation (Ser334Pro) in the catalytic domain and a substitution (Glu102Lys) in the second EGF-like domain. Br J Haematol 1995; 90: 910-5.
79. Bezeaud A, Miyata T, Zheng YZ, et al. Functional consequences of ser-334 to pro mutation in a factor-X variant (factor-X Marseilles). Thromb Haemost 1993; 69: 617.
80. De Stefano V, Leone G, Ferrelli R, Hassan HJ, Macioce G, Bizzi B. Factor X Roma - a congenital factor X variant defective at different degrees in the intrinsic and the extrinsic activation. Br J Haematol 1988; 69: 387-91.
81. Odom MW, Leone G, De SV, et al. Five novel point mutations: two causing haemophilia B and three causing factor X deficiency. Mol Cell Probes 1994; 8: 63-65.
82. Kim DJ, Thompson AR, Nash DR, James HL. Factor X Wenatchee I and Wenatchee II: documentation of an incidence of compound heterozygosity and partial characterization of the variant proteins. Blood 1993; 65: 247.
83. James HL, Kumar A, Thompson AR, Fair DS. A point mutation destroys a processing site between the light and heavy chains of factor X Wenatchee. FASEB 1991; 5: 1661.
84. Messier TL, Wong C, Bovill EG, Long GL, Church WR. Factor X Stockton: a mild bleeding diathesis associated with an active site mutation in factor X. Blood Coag Fibrinol 1996; 7: 5-14.
85. Vienna. Thromb Haemost 1993; 69: 1452.
86. Huhmann I, Höller B, Krinninger B, et al. Factor X Frankfurt I: molecular and functional characterisation of a hereditary factor X defect (Gla+25→Lys). Blood 1995; 86: 3482.
87. Wallmark A, Larson P, Ljung R, Monroe D, High K. Molecular defect (Gla26→Asp) and its functional consequencs in a hereditary factor X deficiency (Factor X Malmo 4). Blood 1991; 78 suppl 1: 60.
88. Wallmark A, Ho C, Monroe DM, Tengborn L, High KA. Molecular defect in factor X Öckerö, a mild congenital factor X deficiency. Thromb Haemost 1991; 65: 1263.
89. Goldsmith GH, Pence RE, Ratnoff OD, Adelstein DJ, Furie B. Studies on a family with combined deficiencies of vitamin K-dependent coagulation factors. J Clin Invest 1982; 69: 1253-60.
90. Vincente V, Maria R, Alberca I, Tamagnini GPT, Borrasca AL. Congenital deficiency of vitamin-K dependent coagulation factors and protein C. Thromb Haemost 1984; 51: 343-6.
91. Soff GA, Livein J. Familial multiple coagulation deficiencies: combined factor II, VII, IX and S deficiency. Semin Thromb Hemost 1981; 7: 133-8.
92. Kroll AJ, Alexander B, Cochizo F, Pechet L. Hereditary deficiencies of clotting factors VII and X associated with carotid body tumours. N Engl J Med 1964; 270: 6-13.
93. Korsan-Bengsten L, Hjort PF, Ygge J. Acquired factor X deficiency in a patient with amyloidosis. Thromb Diath Haemorh 1962; 7: 558-66.
94. Krause TR. Acquired factor X deficiency and amyloidosis. Am J Clin Pathol 1977; 67: 170-3.
95. Howell M. Acquired factor X deficiency associated with systemic amyloidosis. A report of a case. Blood 1963; 21: 739-44.
96. Pechet L, Kastrul JJ. Amyloidosis associated with factor X (Stuart) deficiency: a case report. Ann Intern Med 1964; 61: 315-8.
97. Furie B, Greene E, Furie BC. Syndrome of acquired factor X deficiency and systemic amyloidosis: in vivo studies of the metabolic fate of factor X. N Engl J Med 1977; 297: 81-5.
98. Furie B, Voo L, McAdam K, Furie BC. Mechanism of factor X deficiency in systemic amyloidosis. N Engl J Med 1981; 304: 827-30.
99. Glenner G. Factor X deficiency and systemic amyloidosis. N Engl J Med 1977; 297: 108-9.
100. Camoriano JK, Greipp PR, Bayer GK, Bowie E. Resolution of acquired factor X deficiency and amyloidosis with melphalan and prednisolone therapy. N Engl J Med 1987; 316: 1133-5.
101. Greipp PR, Kyle RA, Bowie EJW. Factor X deficiency in primary amyloidosis. Resolution after splenectomy. N Engl J Med 1979; 301: 1050-1.
102. Rosenstein ED, Itzkowitz SH, Penziner AS, et al. Resolution of factor X deficiency in primary amyloidosis following splenectomy. Arch Intern Med 1983; 143: 597-9.
103. Schwarzinger I, Stainkos M, Bettelheim P, et al. Recurrent, isolated factor-X deficiency in myeloma - repeated normalization of factor-X levels after cystostatic chemotherapy followed by late treatment failure associated with the development of systemic amyloidosis. Thromb Haemost 1992; 68: 648-51.
104. Graham JB, Barrow EM, Wynne TR. Stuart Clotting defect III. An acquired case with complete recovery. In: Brinkhous KM, Nicola PDE, eds. Hemophilia and Other Hemorrhagic States. Chapel Hill: University of North Carolina, 1959; 158.
105. Nora RE, Bell WR, Noe DA, Sholar PW. Novel factor X deficiency. Normal partial thromboplastin time and associated spindle cell thymoma. Am J Med 1985; 79: 122-6.
106. Carter C, Winfield DA. Factor X deficiency during treatment of relapsed acute myeloid leukaemia with amsarcrine. Clin Lab Haematol 1988; 10: 225-8.
107. Stefanini N, Wiggishoff C. Stuart factor (Factor X) deficiency associated with renal and adrenal insufficiency. Ann Intern Med 1966; 64: 1285-91.
108. Ness PM, Hymas PG, Gesme D, Perkins HA. An unusual factor-X inhibitor in leprosy. Am J Hematol 1980; 8: 397-402.
109. Peuscher FW, Van Aken WG, Van Mourik JA. Acquired, transient factor X (Stuart factor) deficiency in a patient with Mycoplasma pneumonia infection. Scand J Heamato 1979; 23: 257-64.
110. Mulhare PE, Tracy PB, Golden EA, Branda RF, Bovill EG. A case of acquired factor X deficiency with in vivo and in vitro evidence of inhibitor activity directed against Factor X. Am J Clin Pathol 1991; 96: 196-200.
111. Lankiewicz MW, Bell WR. A unique circulating inhibitor with specificity for coagulation factor X. Am J Med 1992; 93: 343-6.
112. Liles DK, White GC, Delamastro D, Roberts HR. In-vitro characterization of an acquired factor-X inhibitor. Blood 1993; 82: 596.
113. Condie RG. A serial study of coagulation factors XII, XI and X in plasma in normal pregnancy complicated by preeclampsia. Br J Obs Gynae 1976; 83: 636-9.
114. Kumar M, Mehta P. Congenital coagulopathies and pregnancy - report of 4 pregnancies in a factor X-deficient woman. Am J Haematol 1994; 46: 241-4.